US Dollar vs Yen

ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。

登録

ホーム
投資
株式
アメリカ
NASDAQ
Chemomab Therapeutics Ltd (CMMB)
Chemomab Therapeutics Ltd (CMMB) ニュース

CMMB

Chemomab Therapeutics (CMMB)

Chemomab Therapeutics Ltd

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:CMMB

1 2 3 4 5 6 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/02	20 : 00	GlobeNewswire Inc.	Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference	NASDAQ:CMMB	Chemomab Therapeutics Ltd
2024/04/24	20 : 00	GlobeNewswire Inc.	Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update	NASDAQ:CMMB	Chemomab Therapeutics Ltd
2024/04/18	20 : 00	GlobeNewswire Inc.	Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis	NASDAQ:CMMB	Chemomab Therapeutics Ltd
2024/04/02	20 : 00	GlobeNewswire Inc.	Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024	NASDAQ:CMMB	Chemomab Therapeutics Ltd
2024/03/25	20 : 06	GlobeNewswire Inc.	Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis	NASDAQ:CMMB	Chemomab Therapeutics Ltd
2024/03/07	21 : 00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CMMB	Chemomab Therapeutics Ltd
2024/03/07	21 : 00	PR Newswire (US)	Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate Update	NASDAQ:CMMB	Chemomab Therapeutics Ltd
2024/03/05	21 : 00	PR Newswire (US)	Chemomab Therapeutics to Participate in Leerink Global BioPharma Conference	NASDAQ:CMMB	Chemomab Therapeutics Ltd
2024/02/20	23 : 20	AllPennyStocks.com	Biotech Shares Massively Bid Up Before Opening Bell	NASDAQ:CMMB	Chemomab Therapeutics Ltd
2024/02/20	21 : 00	PR Newswire (US)	Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases	NASDAQ:CMMB	Chemomab Therapeutics Ltd
2024/02/14	21 : 00	PR Newswire (US)	Chemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update	NASDAQ:CMMB	Chemomab Therapeutics Ltd
2024/02/05	21 : 00	PR Newswire (US)	Chemomab Therapeutics to Participate in Upcoming Investor Conferences	NASDAQ:CMMB	Chemomab Therapeutics Ltd
2024/01/30	21 : 00	PR Newswire (US)	Chemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis	NASDAQ:CMMB	Chemomab Therapeutics Ltd
2024/01/03	21 : 00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CMMB	Chemomab Therapeutics Ltd
2024/01/03	21 : 00	PR Newswire (US)	Chemomab Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary Sclerosing Cholangitis Trial and Moves Up Expected Topline Readout to Midyear 2024	NASDAQ:CMMB	Chemomab Therapeutics Ltd
2023/11/16	21 : 00	PR Newswire (US)	Chemomab Presentation at ACR Convergence 2023 Provides Further Support for Key Role of Its CCL24 Target in the Pathogenesis of Systemic Sclerosis	NASDAQ:CMMB	Chemomab Therapeutics Ltd
2023/11/16	06 : 35	Edgar (US Regulatory)	Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]	NASDAQ:CMMB	Chemomab Therapeutics Ltd
2023/11/15	21 : 00	PR Newswire (US)	Chemomab Therapeutics Receives FDA Fast Track Designation for CM-101 for the Treatment of Primary Sclerosing Cholangitis	NASDAQ:CMMB	Chemomab Therapeutics Ltd
2023/11/13	22 : 00	PR Newswire (US)	Chemomab Presents New Clinical Data Supporting CM-101's Anti-Fibrotic/Anti-Inflammatory Activity in Patients with Liver Fibrosis and New Data Highlighting Unique Association of Its CCL24 Target with Key PSC Pathways at AASLD's The Liver Meeting® 2023	NASDAQ:CMMB	Chemomab Therapeutics Ltd
2023/11/09	22 : 00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CMMB	Chemomab Therapeutics Ltd
2023/11/09	22 : 00	PR Newswire (US)	Chemomab Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update	NASDAQ:CMMB	Chemomab Therapeutics Ltd
2023/11/07	06 : 15	PR Newswire (US)	Chemomab Therapeutics Discloses Receipt of Nasdaq Notice Regarding Minimum Bid Price Requirement	NASDAQ:CMMB	Chemomab Therapeutics Ltd
2023/11/06	14 : 15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:CMMB	Chemomab Therapeutics Ltd
2023/10/30	21 : 33	Edgar (US Regulatory)	Form F-3/A - Registration statement by foreign private issuers: [Amend]	NASDAQ:CMMB	Chemomab Therapeutics Ltd
2023/10/30	20 : 00	PR Newswire (US)	Chemomab Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update	NASDAQ:CMMB	Chemomab Therapeutics Ltd
2023/10/26	20 : 00	PR Newswire (US)	Chemomab Therapeutics to Present at Upcoming Scientific Conferences	NASDAQ:CMMB	Chemomab Therapeutics Ltd
2023/10/17	05 : 25	Edgar (US Regulatory)	Form F-3 - Registration statement by foreign private issuers	NASDAQ:CMMB	Chemomab Therapeutics Ltd
2023/09/28	20 : 00	PR Newswire (US)	Chemomab Therapeutics to Present Its CM-101 Clinical Program in Primary Sclerosing Cholangitis at 2023 Roth MKM Healthcare Opportunities Conference	NASDAQ:CMMB	Chemomab Therapeutics Ltd
2023/08/29	20 : 00	PR Newswire (US)	Chemomab Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference	NASDAQ:CMMB	Chemomab Therapeutics Ltd
2023/08/14	21 : 05	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CMMB	Chemomab Therapeutics Ltd

Showing the most relevant articles for your search:NASDAQ:CMMB

1 2 3 4 5 6 次へ >>

US Dollar vs Yen

Invesco QQQ Trust Series 1

Health Care Select Sector

JP Morgan Chase

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約